Galderma Presents New Nemolizumab Data at EADV Reinforcing Rapid Onset of Action and Consistent Relief of Symptoms for People With Prurigo Nodularis and Atopic Dermatitis
LAUSANNE, Switzerland--(BUSINESS WIRE)--Galderma immediately introduced the presentation of recent section 2 knowledge supporting the efficacy of its investigational monoclonal antibody, ...
